The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Male hypogonadism is a condition in which the body doesn't produce enough of the hormone that plays a key role in masculine growth and development during puberty (testosterone) or enough sperm or both. You can be born with male hypogonadism, or it can develop later in life, often from injury or infection.
The global Male Hypogonadism market was valued at US$ 3040.6 million in 2023 and is anticipated to reach US$ 3721.7 million by 2030, witnessing a CAGR of 2.5% during the forecast period 2024-2030.
North American market for Male Hypogonadism is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Male Hypogonadism is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Male Hypogonadism in Kallmann Syndrome is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Male Hypogonadism include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd. and Finox Biotech, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Male Hypogonadism, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Male Hypogonadism.
Report Scope
The Male Hypogonadism market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Male Hypogonadism market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Male Hypogonadism companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Astrazeneca Plc.
- Merck & Co. Inc.
- Laboratories Genevrier
- Allergan Plc.
- Endo International Plc.
- Ferring
- AbbVie Inc.
- Eli Lilly and Company Ltd.
- Finox Biotech
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- IBSA Institut Biochimque
Segment by Type
- Testosterone Replacement Therapy
- Gonadotropin-Releasing Hormones Therapy
Segment by Application
- Kallmann Syndrome
- Klinefelters Syndrome
- Pituitary Disorders
- Others
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Male Hypogonadism companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Male Hypogonadism Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Testosterone Replacement Therapy
1.2.3 Gonadotropin-Releasing Hormones Therapy
1.3 Market by Application
1.3.1 Global Male Hypogonadism Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Kallmann Syndrome
1.3.3 Klinefelters Syndrome
1.3.4 Pituitary Disorders
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Male Hypogonadism Market Perspective (2019-2030)
2.2 Male Hypogonadism Growth Trends by Region
2.2.1 Global Male Hypogonadism Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Male Hypogonadism Historic Market Size by Region (2019-2024)
2.2.3 Male Hypogonadism Forecasted Market Size by Region (2025-2030)
2.3 Male Hypogonadism Market Dynamics
2.3.1 Male Hypogonadism Industry Trends
2.3.2 Male Hypogonadism Market Drivers
2.3.3 Male Hypogonadism Market Challenges
2.3.4 Male Hypogonadism Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Male Hypogonadism Players by Revenue
3.1.1 Global Top Male Hypogonadism Players by Revenue (2019-2024)
3.1.2 Global Male Hypogonadism Revenue Market Share by Players (2019-2024)
3.2 Global Male Hypogonadism Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Male Hypogonadism Revenue
3.4 Global Male Hypogonadism Market Concentration Ratio
3.4.1 Global Male Hypogonadism Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Male Hypogonadism Revenue in 2023
3.5 Male Hypogonadism Key Players Head office and Area Served
3.6 Key Players Male Hypogonadism Product Solution and Service
3.7 Date of Enter into Male Hypogonadism Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Male Hypogonadism Breakdown Data by Type
4.1 Global Male Hypogonadism Historic Market Size by Type (2019-2024)
4.2 Global Male Hypogonadism Forecasted Market Size by Type (2025-2030)
5 Male Hypogonadism Breakdown Data by Application
5.1 Global Male Hypogonadism Historic Market Size by Application (2019-2024)
5.2 Global Male Hypogonadism Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Male Hypogonadism Market Size (2019-2030)
6.2 North America Male Hypogonadism Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Male Hypogonadism Market Size by Country (2019-2024)
6.4 North America Male Hypogonadism Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Male Hypogonadism Market Size (2019-2030)
7.2 Europe Male Hypogonadism Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Male Hypogonadism Market Size by Country (2019-2024)
7.4 Europe Male Hypogonadism Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Male Hypogonadism Market Size (2019-2030)
8.2 Asia-Pacific Male Hypogonadism Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Male Hypogonadism Market Size by Region (2019-2024)
8.4 Asia-Pacific Male Hypogonadism Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Male Hypogonadism Market Size (2019-2030)
9.2 Latin America Male Hypogonadism Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Male Hypogonadism Market Size by Country (2019-2024)
9.4 Latin America Male Hypogonadism Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Male Hypogonadism Market Size (2019-2030)
10.2 Middle East & Africa Male Hypogonadism Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Male Hypogonadism Market Size by Country (2019-2024)
10.4 Middle East & Africa Male Hypogonadism Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astrazeneca Plc.
11.1.1 Astrazeneca Plc. Company Detail
11.1.2 Astrazeneca Plc. Business Overview
11.1.3 Astrazeneca Plc. Male Hypogonadism Introduction
11.1.4 Astrazeneca Plc. Revenue in Male Hypogonadism Business (2019-2024)
11.1.5 Astrazeneca Plc. Recent Development
11.2 Merck & Co. Inc.
11.2.1 Merck & Co. Inc. Company Detail
11.2.2 Merck & Co. Inc. Business Overview
11.2.3 Merck & Co. Inc. Male Hypogonadism Introduction
11.2.4 Merck & Co. Inc. Revenue in Male Hypogonadism Business (2019-2024)
11.2.5 Merck & Co. Inc. Recent Development
11.3 Laboratories Genevrier
11.3.1 Laboratories Genevrier Company Detail
11.3.2 Laboratories Genevrier Business Overview
11.3.3 Laboratories Genevrier Male Hypogonadism Introduction
11.3.4 Laboratories Genevrier Revenue in Male Hypogonadism Business (2019-2024)
11.3.5 Laboratories Genevrier Recent Development
11.4 Allergan Plc.
11.4.1 Allergan Plc. Company Detail
11.4.2 Allergan Plc. Business Overview
11.4.3 Allergan Plc. Male Hypogonadism Introduction
11.4.4 Allergan Plc. Revenue in Male Hypogonadism Business (2019-2024)
11.4.5 Allergan Plc. Recent Development
11.5 Endo International Plc.
11.5.1 Endo International Plc. Company Detail
11.5.2 Endo International Plc. Business Overview
11.5.3 Endo International Plc. Male Hypogonadism Introduction
11.5.4 Endo International Plc. Revenue in Male Hypogonadism Business (2019-2024)
11.5.5 Endo International Plc. Recent Development
11.6 Ferring
11.6.1 Ferring Company Detail
11.6.2 Ferring Business Overview
11.6.3 Ferring Male Hypogonadism Introduction
11.6.4 Ferring Revenue in Male Hypogonadism Business (2019-2024)
11.6.5 Ferring Recent Development
11.7 AbbVie Inc.
11.7.1 AbbVie Inc. Company Detail
11.7.2 AbbVie Inc. Business Overview
11.7.3 AbbVie Inc. Male Hypogonadism Introduction
11.7.4 AbbVie Inc. Revenue in Male Hypogonadism Business (2019-2024)
11.7.5 AbbVie Inc. Recent Development
11.8 Eli Lilly and Company Ltd.
11.8.1 Eli Lilly and Company Ltd. Company Detail
11.8.2 Eli Lilly and Company Ltd. Business Overview
11.8.3 Eli Lilly and Company Ltd. Male Hypogonadism Introduction
11.8.4 Eli Lilly and Company Ltd. Revenue in Male Hypogonadism Business (2019-2024)
11.8.5 Eli Lilly and Company Ltd. Recent Development
11.9 Finox Biotech
11.9.1 Finox Biotech Company Detail
11.9.2 Finox Biotech Business Overview
11.9.3 Finox Biotech Male Hypogonadism Introduction
11.9.4 Finox Biotech Revenue in Male Hypogonadism Business (2019-2024)
11.9.5 Finox Biotech Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Male Hypogonadism Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Male Hypogonadism Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.11 Bayer AG
11.11.1 Bayer AG Company Detail
11.11.2 Bayer AG Business Overview
11.11.3 Bayer AG Male Hypogonadism Introduction
11.11.4 Bayer AG Revenue in Male Hypogonadism Business (2019-2024)
11.11.5 Bayer AG Recent Development
11.12 IBSA Institut Biochimque
11.12.1 IBSA Institut Biochimque Company Detail
11.12.2 IBSA Institut Biochimque Business Overview
11.12.3 IBSA Institut Biochimque Male Hypogonadism Introduction
11.12.4 IBSA Institut Biochimque Revenue in Male Hypogonadism Business (2019-2024)
11.12.5 IBSA Institut Biochimque Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
